As phase IV and observational studies tend to be more commercial in nature, successfully planning and implementing them can be a major challenge, especially in terms of motivating investigators and recruiting patients who may already have access to the latest medications. Observational data whilst demonstrating actual patient and prescriber behaviour also presents the additional challenge of the issue of bias and regulatory acceptance.
This event will be a 3 day forum, structured to provide the latest and most value-adding, real-life experiences in post-marketing studies, including their benefits and challenges. The event will be focused on the strategic use of late phase studies and it will be an ideal opportunity for benchmarking and networking with the experts and will bring the post-marketing community together to discuss solutions to the challenges in this vital area of research.
Participants will leave with a clear understanding of the vital role that late-phase research can play to satisfy regulators and payers and facilitate the market & patient access process & how to engage KOLs and investigators effectively for maximum evidence generation.
For more detailed information on each stream of the event, please click on the stream on the left-hand side of this page.
We look forward to meeting you in Brussels!
Who Will Benefit:
Pharmaceutical, Biotech and Medical Device Companies:
Vice Presidents, Directors & Managers of: Medical Affairs, Epidemiology, Clinical Development & Operations, Drug Safety, Health Outcomes, Pharmacovigilance, Data Management, Regulatory Affairs, Clinical Outsourcing.
CROs, EDC & Data Management, Clinical Software, Market Access & Health Outcomes Consultancies.
Academics & Doctors:
Epidemiology, Principle Investigators.
Ministries of Health, Regulatory & Health Technology Assessment Agencies.